Retatrutide

What is Retatrutide?

Retatrutide is a 39-amino-acid synthetic peptide developed as a unimolecular triple agonist of GLP-1, GIP, and glucagon receptors. It is one of the most studied next-generation incretin-class molecules and is currently progressing through late-stage clinical trials (Phase III as of 2025-2026) for obesity and metabolic disease under the Eli Lilly designation LY3437943. Research-grade retatrutide is used in preclinical receptor pharmacology and metabolic models.

Mechanism of action (preclinical evidence)

Retatrutide achieves its metabolic profile through balanced triple agonism of three incretin and counter-regulatory receptors: GLP-1R, GIP-R, and the glucagon receptor. GLP-1R activation on pancreatic β-cells stimulates glucose-dependent insulin secretion, suppresses glucagon release from α-cells, slows gastric emptying, and reduces appetite via central nervous system effects in the hypothalamus and brainstem. GIP-R activation reinforces insulin secretion (the incretin effect) and acts on adipose tissue to modulate lipid metabolism; the dual GIP/GLP-1 axis (also seen in tirzepatide) has been shown to produce more weight loss than GLP-1 alone in clinical trials. The novel third axis - glucagon receptor activation - is the differentiator. Glucagon signaling in the liver normally raises hepatic glucose output, a counter-regulatory action that would oppose the glucose-lowering effects of GLP-1. However, glucagon also drives energy expenditure through fat oxidation, brown adipose tissue activation, and increased basal metabolic rate. In a balanced triple agonist, the energy-expenditure boost from glucagon agonism appears to dominate over the unwanted hepatic glucose-output increase, producing a metabolic shift toward energy use and weight loss without significant hyperglycemia. The precise tuning of agonist potency across the three receptors (Retatrutide is designed to be roughly equipotent on GLP-1R and GIP-R, with somewhat lower activity on glucagon-R) underlies its preclinical and Phase 2 efficacy profile.

Research applications

• Multi-receptor agonist receptor binding and selectivity studies
• Adipocyte and hepatic metabolic models
• Comparative pharmacology vs single-agonists (semaglutide, tirzepatide)
• Energy expenditure and food intake rodent models
• GLP-1/GIP/glucagon signaling pathway research

Storage and handling

Store lyophilised retatrutide at -20 °C in a sealed, desiccant-protected vial. Once reconstituted, large peptides like retatrutide are particularly susceptible to surface adsorption and freeze-thaw degradation; aliquot in low-protein-binding tubes and minimize repeated thawing.

Regulatory status

Retatrutide is currently an investigational drug in clinical trials. It is NOT approved by FDA, EMA, or any other regulator for any indication as of 2026. Supplied strictly for laboratory research; not for human or veterinary use.

Frequently asked questions